Level Biotechnology (TWO:3118) — Market Cap & Net Worth
Market Cap & Net Worth: Level Biotechnology (3118)
Level Biotechnology (TWO:3118) has a market capitalization of $31.95 Million (NT$1.01 Billion) as of June 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #23598 globally and #1490 in its home market, demonstrating a -7.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Level Biotechnology's stock price NT$31.25 by its total outstanding shares 32452900 (32.45 Million). Review Level Biotechnology (3118) financial obligations to assess the company's total debt and financial obligations.
Level Biotechnology Market Cap History: 2015 to 2026
Level Biotechnology's market capitalization history from 2015 to 2026. Data shows growth from $26.14 Million to $31.95 Million (2.49% CAGR).
Level Biotechnology Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Level Biotechnology's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Level Biotechnology's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Level Biotechnology's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $24.47 Million | $577.63 Million | $68.31 Million | 0.04x | 0.36x |
| 2018 | $22.67 Million | $629.03 Million | $38.91 Million | 0.04x | 0.58x |
| 2019 | $22.43 Million | $638.90 Million | $47.40 Million | 0.04x | 0.47x |
| 2020 | $25.80 Million | $672.49 Million | $58.04 Million | 0.04x | 0.44x |
| 2021 | $27.17 Million | $677.28 Million | $68.18 Million | 0.04x | 0.40x |
| 2022 | $26.76 Million | $593.01 Million | $58.47 Million | 0.05x | 0.46x |
| 2023 | $31.13 Million | $660.61 Million | $62.91 Million | 0.05x | 0.49x |
| 2024 | $32.72 Million | $731.35 Million | $64.81 Million | 0.04x | 0.50x |
Competitor Companies of 3118 by Market Capitalization
Companies near Level Biotechnology in the global market cap rankings as of June 18, 2026.
Key companies related to Level Biotechnology by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Level Biotechnology Historical Marketcap From 2015 to 2026
Between 2015 and today, Level Biotechnology's market cap moved from $26.14 Million to $ 31.95 Million, with a yearly change of 2.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$31.95 Million | -5.30% |
| 2025 | NT$33.74 Million | +3.12% |
| 2024 | NT$32.72 Million | +5.09% |
| 2023 | NT$31.13 Million | +16.33% |
| 2022 | NT$26.76 Million | -1.49% |
| 2021 | NT$27.17 Million | +5.31% |
| 2020 | NT$25.80 Million | +15.05% |
| 2019 | NT$22.43 Million | -1.06% |
| 2018 | NT$22.67 Million | -7.37% |
| 2017 | NT$24.47 Million | +13.40% |
| 2016 | NT$21.58 Million | -17.45% |
| 2015 | NT$26.14 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Level Biotechnology was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.95 Million USD |
| MoneyControl | $31.95 Million USD |
| MarketWatch | $31.95 Million USD |
| marketcap.company | $31.95 Million USD |
| Reuters | $31.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more